Overview of therapeutic drug research for COVID-19 in China.

Overview of therapeutic drug research for COVID-19 in China.
Acta Pharmacol Sin. 2020 Jun 17;:
Authors: Li H, Yang L, Liu FF, Ma XN, He PL, Tang W, Tong XK, Zuo JP
Abstract
Since the outbreak of novel coronavirus pneumonia (COVID-19) in December 2019, more than 2,500,000 people worldwide have been diagnosed with SARS-CoV-2 as of April 22. In response to this epidemic, China has issued seven trial versions of diagnosis and treatment protocol for COVID-19. According to the information that we have collected so far, this article provides an overview of potential therapeutic drugs and compounds with much attention, including favipiravir and hydroxychloroquine, as well as traditional Chinese medicine, which have been reported with good clinical treatment effects. Moreover, with further understanding of SARS-CoV-2 virus, new drugs targeting specific SARS-CoV-2 viral components arise and investigations on these novel anti-SARS-CoV-2 agents are also reviewed.
PMID: 32555446 [PubMed - as supplied by publisher]

Source: Acta Pharmacologica Sinica - June 16, 2020 Category: Drugs & Pharmacology Authors: Li H, Yang L, Liu FF, Ma XN, He PL, Tang W, Tong XK, Zuo JP Tags: Acta Pharmacol Sin Source Type: research